Atlas Trials

Empagliflozin as Adjunctive to Insulin Therapy Over 26 Weeks in Patients With T1DM (EASE-3)

Clinical trial NCT02580591 · COMPLETED

Trial details

NCT number
NCT02580591
Sponsor
Boehringer Ingelheim
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Diabetes Mellitus, Type 1
Start date
2015-12-22
Primary completion
2017-09-12
Enrollment
977

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.